Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And with our recent financing, we remain in a strong financial position, which enables us to invest aggressively in research, development and precommercial activities to maximize the value of Ziftomenib and support our other pipeline assets |
| We're encouraged that the strong operational execution seen in the Ziftomenib trials has carried over to the FIT-001 study and look forward to realizing the promise of the combinations |
| But ultimately, that's better for patients, offers them a better clinical benefit and is arguably a more compelling commercial case |
| But you can imagine, we're already putting the designs together on the basis of the data we've generated thus far, right? Based on what we're seeing in the 007 study, I think we're highly encouraged |
| I think we'll be well positioned |
| We believe a best-in-class safety and activity profile and optimum pharmaceutical properties will enable Ziftomenib to become a cornerstone of therapy for patients with acute leukemias |
| And I think Zifto is well positioned there, but there's not for people who are looking for some kind of knockout blow, that's not coming, right? This is going to be a multi-player, hopefully multi-billion dollar market that's really good for patients |
| And I think that's highly encouraging of the clinical benefit that these menin inhibitors can provide |
| Importantly, we are encouraged that Tipifarnib continues to demonstrate a favorable safety and tolerability profile at its full dose in combination with Alpelisib |
| What does appear to be clear is that menin inhibitors plus ven are better than ven alone |
| And so, I think we're feeling optimistic that we'll be able to find a dose and schedule that gets those two agents working well together |
| Those are the three reasons and we've been extremely pleased by the results |
| 007 is going very robustly and as this 001, I think we have every expectation 008 will as well |
| We also have a growing body of preclinical data that supports attractive opportunities for Menin inhibitors beyond acute leukemias |
| Ziftomenib demonstrated a highly encouraging safety and tolerability profile in combination with cytarabine plus daunorubicin or 7+3 as well as with Venetoclax plus Azacitidine enabling continuous administration of Ziftomenib while effectively mitigating the risk of differentiation syndrome |
| I think you can hear from us, we're encouraged thus far by what we're seeing |
| I think that was very good advice |
| We still have lots of time until that happens, and we're making good progress |
| Preclinical data for Ziftomenib in combination with FLT3 inhibitors demonstrates strong synergistic effects compared to either single agent alone |
| But the potential Jonathan to have an all-oral regimen that could drive such a profound clinical benefit in patients we think would be very attractive |
| Continuous daily dosing of Ziftomenib at 200 milligrams QD was well tolerated and the safety profile was consistent with features of underlying disease and backbone therapies |
| So we're holding those cards a little closer to the vest, but we're quite excited |
| They made a $25 million equity investment and we have a continued good relationship with them |
| This belief is supported by growing investigator enthusiasm as evidenced by rapid enrollment across all of our ongoing Ziftomenib studies |
| We have every reason to believe as we go into combinations, as we go earlier, durability will improve |
| Meanwhile, we continue to evaluate our first generation FTI Tipifarnib in combination with the targeted therapy Alpelisib, building on impressive clinical benefit we observed with Tipifarnib alone in head and neck cancer |
| The more data we generate with Zifto, the more excited we become |
| Maybe there are some updates today from the competition, but our enrollment continues to be robust |
| Number two is, if we could provide those patients with an all oral targeted therapy regimen that was effective and well tolerated, we think that would be broadly embraced |
| The LDAC combination might be very attractive in Europe |
| Statement |
|---|
| In the meantime, we're now dosing patients in our KOMET-008 study of Ziftomenib in combination with additional standards of care, including the FLT3 inhibitor, Gilteritinib, FLAG-IDA or LDAC, all for the treatment of relapsed refractory NPM1 mutant or KMT2A rearranged AML, roughly half of patients with relapsed or refractory NPM1 mutant AML have cooccurring FLT3 mutations and the prognosis for these patients is particularly poor |
| And as you know from the monotherapy, there's nothing that we've seen that really gives us cause for concern, but one still has to run the experiment |
| Enrollment is difficult to argue with |
| So the yes, you will by design cannibalize those later lines if you're successful |
| And we're waiting to share the translational data until we're further along toward execution of the clinical experiment because let's be honest, this is a competitive field |
| Net loss for the full-year of 2023 was $152.6 million compared to a net loss of $135.8 million for the prior year |
| Net loss for the fourth quarter of 2023 was $42.8 million compared to a net loss of $33.1 million for the fourth quarter of 2022 |
| We know we're going to attract competition |
Please consider a small donation if you think this website provides you with relevant information